• Preparing For Commercial Launch In Oncology With Candel Therapeutics' Paul Peter Tak, M.D., Ph.D.
    Nov 16 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Paul Peter Tak, M.D., Ph.D., CEO at Candel Therapeutics, talks about the path from Phase 3 data to BLA submission for aglatimagene in localized prostate cancer and why “in situ immunization” could change how solid tumors are treated. He also talks through leadership and operating choices for minimizing risk in late-stage development, how FDA's Fast Track and RMAT designations aided communication and CMC planning, and how an outsourced commercial model can help companies prepare for launch and avoid premature fixed costs.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


    Show More Show Less
    56 mins
  • Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley
    Nov 9 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients. Sean shares details about his neuroscience portfolio strategy at AbbVie, and how biomarkers in clinical development, plus dosing and formulation, can matter as much as the molecule itself. He also discusses partnering in China, and the potential for psychedelics in treating psychiatric disorders, including bretisilocin, AbbVie's first psychedelic clinical program.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


    Show More Show Less
    50 mins
  • Translating A New Discovery Into A Novel Cancer Therapy With Grid Therapeutics' Ned Patz, M.D.
    Nov 2 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Edward (Ned) Patz, M.D., Cofounder and CEO at Grid Therapeutics, explains how a Duke University lab discovery turned into Grid Therapeutics and two clinical-stage cancer immunotherapy programs. Ned talks about discovering the human-derived antibody treatment GT103 and novel Compliment Factor H (CFH) target, the messy realities of funding a new therapeutic approach in cancer, and the leadership lessons that come with running a scrappy virtual biotech.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


    Show More Show Less
    54 mins
  • Bioprinting 3D Human Tissue To Discover And Test New Treatments With Viscient Bio's Keith Murphy
    Oct 26 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Keith Murphy, CEO at Viscient Biosciences, unpacks how 3D human tissue models and scaffold-free bioprinting can change the way developers predict drug safety and model disease. Keith traces his professional journey from MIT and Amgen, to founding Organovo and building Viscient and VivoSim (formerly Organovo) into companies that push New Approach Methodologies (NAM) adoption and smarter, more efficient drug development. Keith also shares policy ideas the FDA could use to further incentivize the use of NAMs.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


    Show More Show Less
    57 mins
  • Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.
    Oct 19 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Bret Bostwick, M.D., Venture Partner at Breyer Capital, a family office, talks about his path from medical geneticist to CNS drug development and biotech investing. Bret reflects on lessons he learned at Alnylam about the power of genetically validated drug targets and the importance of team culture, why CNS drug development fails so often, and the problem with animal models. He also talks about where AI is truly helping early-stage biotechs, and where it can create problems.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


    Show More Show Less
    47 mins
  • AI, China, And Biotech Investing With SR One's Simeon George, M.D.
    Oct 12 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Simeon George, M.D., Cofounder and CEO at SR One Capital Management, returns to the show to talk about how SR One evaluates biotech investment targets, and the good and bad signs that emerge during diligence. Simeon also discusses a new report published by SR One on how AI and China are changing the strategy and playbook for new drug creation.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


    Show More Show Less
    49 mins
  • Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding
    Oct 5 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to transform cancer cells into immune therapy-producing factories in vivo. Cyriac also discusses China’s newest five-year plan for biotech (2026 to 2030), why U.S. funding cycles are pushing innovation offshore, and how a U.S. sovereign wealth fund could support preclinical and early-stage drug development leadership at home.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


    Show More Show Less
    1 hr
  • Growing And Scaling A Radiopharmaceuticals Company With AdvanCell's Philina Lee, Ph.D.
    Sep 28 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Philina Lee, Ph.D., CEO at AdvanCell, explains how lead-based targeted alpha therapies can unlock deeper, more durable cancer responses, and why radiopharmaceutical companies live or die by manufacturing. Philina talks about AdvanCell's recent oversubscribed $315 million Series D raise, the company's vertically integrated manufacturing capability, and future plans for a regional U.S. manufacturing network. She also reflects on the current targeted alpha therapy landscape and how it could evolve over the next few years.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


    Show More Show Less
    55 mins